AZD5851 for Liver Cancer
(ATHENA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called AZD5851 for individuals with advanced or recurrent hepatocellular carcinoma (HCC). The goal is to evaluate AZD5851's effectiveness in patients whose tumors express the protein GPC3. Suitable candidates have inoperable liver cancer, have not responded to other treatments, and have tumors confirmed as GPC3-positive. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial requires that you stop taking any anticancer therapy at least 21 days before starting the study treatment, or within 5 half-lives of the medication, whichever is shorter. The protocol does not specify about other medications, so it's best to discuss with the trial team.
Is there any evidence suggesting that AZD5851 is likely to be safe for humans?
Research shows that AZD5851 is undergoing its first human trials to assess safety. The researchers have not yet determined how well people can tolerate it or what side effects might occur. As this study begins, the primary aim is to identify potential risks and observe patient responses to the treatment.
Early studies like this one focus on evaluating treatment safety. Although solid data is not yet available, results from this phase contribute to ensuring participant safety before broader use. Prospective participants should note that the current goal is to understand safety and treatment tolerance.12345Why do researchers think this study treatment might be promising?
AZD5851 is unique because it introduces a new approach to treating liver cancer by being used in conjunction with lymphodepleting chemotherapy, which is not common in current treatments. While most liver cancer treatments, like sorafenib or lenvatinib, target specific proteins involved in tumor growth, AZD5851 works differently by potentially enhancing the immune system's ability to fight the cancer. Researchers are excited about AZD5851 because it represents a novel strategy that could offer improved outcomes for patients by combining immune system activation with traditional chemotherapy methods.
What evidence suggests that AZD5851 might be an effective treatment for liver cancer?
Research has shown that AZD5851, a type of CAR-T therapy, may help treat liver cancer. CAR-T therapy modifies a person's immune cells to better attack cancer cells. Early results suggest that AZD5851 can shrink tumors. Initial studies indicate that similar treatments have worked in about 50% of liver cancer patients who have tried many other treatments, which is encouraging. Although human trial data remains limited, the mechanism of this therapy shows promise for those with advanced liver cancer. Participants in this trial will receive AZD5851 following lymphodepleting chemotherapy.12356
Are You a Good Fit for This Trial?
This trial is for adults with advanced or recurrent liver cancer (Hepatocellular Carcinoma) that can't be removed by surgery. Participants must have tried at least one standard treatment, have a specific protein on their tumor (GPC3+), and manage any hepatitis infections. They can't join if they've had HIV, liver transplant, certain blood vessel issues in the liver, severe illnesses or infections, recent hepatic encephalopathy, autoimmune diseases needing strong medication, previous CAR-T therapy targeting GPC3 or other treatments too close to the start of this trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepleting Chemotherapy
Participants receive 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide) before AZD5851 infusion
Treatment
Participants receive AZD5851, a CAR-T therapy directed against GPC3
Follow-up
Participants are monitored for safety, efficacy, and pharmacokinetics of AZD5851
What Are the Treatments Tested in This Trial?
Interventions
- AZD5851
Trial Overview
The study tests AZD5851 in patients with a particular type of liver cancer marked by GPC3+ proteins. It's an early-stage trial to see how safe it is and how well it works. The first phase checks for safety and dosage; the second phase assesses effectiveness against the disease.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Subjects will receive AZD5851 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Citations
A Phase I/II study to evaluate AZD5851 in GPC3+ ...
This first-time in human, single-arm, open-label multicentre Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, ...
NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in ...
This first-time in human, single-arm, open-label multicentre Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics ...
3.
kucancercenter.org
kucancercenter.org/cancer-clinical-trials/find-trial/clinical-trial-results/study00160163A Phase I/II Open-Label Study to Evaluate the Safety ...
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell CAR-T Therapy Directed ...
4.
alphaclinic.ucsf.edu
alphaclinic.ucsf.edu/phase-iii-study-evaluate-azd5851-gpc3-advancedrecurrent-hepatocellular-carcinomaA Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced ...
This first-time in human, single-arm, open-label multicentre Phase I/II study will evaluate the safety, tolerability, anti-tumour activity, cellular kinetics, ...
5.
oncologypipeline.com
oncologypipeline.com/apexonco/asco-2024-preview-new-car-t-target-shows-liver-cancer-promiseASCO 2024 preview – new Car-T target shows liver cancer ...
C-CAR031 has shown a 50% confirmed response rate in its first-in-human study in the tough setting of heavily pretreated liver cancer, with no dose-limiting ...
A Phase I/II Study to Evaluate AZD5851 in GPC3+ ...
The purpose of this study is to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma. Participation eligibility.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.